Jabberwocky
Frumious Bandersnatch
This is an important step forward in psychedelic medicine! The psychedelic trip is not a requisite for the benefits!
N&PD Moderators: Skorpio | someguyontheinternet
Here's my neuropharmacological perspective on the study - and its many limitations:
I'm sorry, but that's something I just don't have time to do.Would you mind typing them out? I am not in a great situation to watch youtube.
We have explored only 80% of the oceans.Somehow I theorize that there's more out there about receptors as we know currently. For example, why does buprenorphine precipitate withdrawal while kratom does not. Or why mu opioid rotation works (somewhat). Why switching from one AD to another can re-start the initial waiting period and side effects. Etc.. so many questions un-answered.
Also profiles can differ heavily between in-vitro and in-vivo (imho, maybe these papers where I read that had flaws). So psilocin might still affect other receptors in vivo but not do so in vitro.
Still need to read the paper though, sorry if I touch answered stuff. Will update![]()
I, by and large, find myself whole-heartedly concurring with the sentiments raised in your post (that we can never over-estimate the scope of our own lack with regard of the "unknown unknowns" which could conceivably exist, or engender within ourselves too great a sense that the standards with which the cutting edge defines its expertise is but a partial & incomplete knowledge, no matter how relatively grand the scheme is, that the potential for what we might hone in the field of chemical neuroscience could be ever more complex or that its roots may reach to undermining our foundations now)…why does buprenorphine precipitate withdrawal while kratom does not…